Profiling and activity screening of Dammarane-type triterpen saponins from Gynostemma pentaphyllum with glucose-dependent insulin secretory activity

Abstract

The global prevalence of type 2 diabetes is increasing rapidly; consequently there is great need for new and novel therapeutic options. Gynostemma pentaphyllum (GP) is a traditional medicinal plant, mainly present in Southeast Asian countries, that has been reported to exert antidiabetic effects, by stimulating insulin secretion. The specific compound responsible for this effect is however as yet unidentified. Screening for discovery and identification of bioactive compounds of an herbal GP extract, was performed in isolated pancreatic islets from spontaneously diabetic Goto-Kakizaki (GK) rats, a model of type 2 diabetes, and from non-diabetic control Wistar rats. From this herbal extract 27 dammarane-type saponins, including two novel compounds, were isolated and their structure was elucidated by mass spectrometry and NMR spectroscopy. One of the dammarane-type triterpenoid showed a glucose-dependent insulin secretion activity. This compound, gylongiposide I, displays unique abilities to stimulate insulin release at high glucose levels (16.7 mM), but limited effects at a low glucose concentration (3.3 mM). Further studies on this compound, also in vivo, are warranted with the aim of developing a novel anti-diabetic therapeutic with glucose-dependent insulinogenic effect.

Introduction

Gynostemma pentaphyllum (Thunb.) Makino (Cucurbitaceae), GP, a traditional medicinal plant found in China, Vietnam, Korea and Japan, is known for containing a large amount of biologically active saponins known as dammarane-type glycosides^1,2. The beneficial effects reported for the dammarane-type glycosides are against numerous diseases, such as cardiovascular disease, hyperlipidemia, inflammations, diabetes and cancer². Currently, more than 170 unique saponins have been isolated from GP extracts^2–11.

One of the dammarane-type glycosides isolated from GP extract is phanoside, a substance with identified structure and potent insulin secretory effect¹². However, this effect is not glucose-dependent, i.e. it is stimulating insulin release at both low and high glucose concentrations¹². Such an action can potentially induce severe hypoglycemia, similar to that of the well-known antidiabetic drug sulfonylurea. Other studies on effects of identical GP extract in patients with drug-naïve type 2 diabetes have demonstrated reduced glycemia and HbA1c levels, and that these effects could be attributed mainly to improved insulin sensitivity^13,14. This was in agreement with results from a study in spontaneously type 2 diabetic Goto-Kakizaki (GK) rats, in which the GP extract reduced hepatic glucose output, i.e. exerted an antidiabetic effect by improving hepatic insulin sensitivity¹⁵. In addition, GP extract improved glycemic control in type 2 diabetic patients who were also treated with the sulfonylurea compound gliclazide¹⁶. Taken together, these findings indicate that the active component(s) in GP can be delivered by oral administration of the extract. However, to determine the exact mechanism of action of the extract, or the active ingredient(s) responsible for the antidiabetic effect(s), we decided to isolate and characterize the active substance(s) with focus on insulin-stimulatory effects. For that purpose, we developed a system with isolated pancreatic islets from either diabetic GK rats¹⁵ and healthy, control Wistar (W) rats. GK rats are non-obese and were developed by repeated breeding of W rats, selected by higher-than-normal serum glucose levels in oral glucose tolerance tests. The GP extract was separated by HPLC into several fractions that were tested for their potential to stimulate insulin secretion from W or GK islets at a low (3.3 mM) or a high (16.7 mM) glucose concentration. One fraction was shown to have a beneficial activity on insulin secretion and therefore the saponins comprising the fraction were further separated and their individual activity tested. By this bioassay-guided investigation of the GP extract, 27 saponins including two new compounds were isolated and the saponin component responsible for the biological activity of the GP extract was identified. The structures of the 27 compounds were elucidated using NMR, LC-MS and GC-MS analysis. To facilitate further studies on structural characterization of dammarane-type saponins, a library consisting of MS data, NMR ¹H and ¹³C chemical shifts and HSQC NMR spectra was established for the 27 compounds.

Results

In order to isolate and characterize the maximum number of saponin structures in the extract, an optimized chromatographic method was developed using a C-18 reverse-phase column (Fig. 1). The extract was fractionated by repeated preparative chromatography and the fractions were further purified by a final isocratic elution. Twenty-seven saponins were characterized and two of them, fractions 12 and 34 had new structures not previously reported. (Table 1 and Fig. 2). A compilation of the structures, NMR ¹H and ¹³C chemical shifts and HSQC NMR spectra is available in the Supplementary Information.

Figure 1.

Preparative HPLC chromatogram, showing the ten sequencial time fractions TF1-TF10 as well as the fractions 1–42.

Table 1.

Saponins isolated and characterized from the GP extract.

Compound 6A
3β,20ξ,21ξ,23ξ-tetrahydroxy-19-oxo-21,24ξ-cyclodammar-25-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C46H74O17	[M + Na]+; calc. 921.4818	[M + Na]+; measured 921.4789	ref.7
Compound 6B
3β,20ξ,21ξ,26-tetrahydroxy-19-oxo-21,23-epoxydammar-24-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C46H74O18	[M + H]+; calc. 915.4948	[M + H]+; measured 915.4930	ref.35
Compound 8
(20S)-3β,20,21-trihydroxy-19-oxodammar-23,25-diene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranosyl-21-O-β-D-glucopyranoside
White amorphous powder	C46H74O18	[M + Na]+; calc. 1067.5397	[M + Na]+; measured 1067.5351	ref.36
Compound 10
3β,20ξ,21ξ-trihydroxy-19-oxodammar-24-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranosyl-21-O-β-D-glucopyranoside
White amorphous powder	C52H86O21	[M + H]+; calc. 1069.5554	[M + H]+; measured 1069.5663	ref.26
Compound 12
(3β,20S,23R)-3,20,23,26-tetrahydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- β-D-glucopyranoside
White amorphous powder	C47H76O18	[M + Na]+; calc. 951.4924	[M + Na]+; measured 951.4863
Compound 15A
3β,20,21-trihydroxydammar-24-en 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- β-D-glucopyranosyl-21-O-β-D-glucopyranoside
White amorphous powder	C53H90O21	[M + Na]+; calc. 1085.5867	[M + Na]+; measured 1085.5857	ref.37
Compound 17B
3β,20,21-trihydroxydammar-24-en 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- 6-O-acetyl-β-D-glucopyranosyl-21-O-β-D-glucopyranoside
White amorphous powder	C55H92O22	[M + Na]+; calc. 1127.5972	[M + Na]+; measured 1127.5899	ref.37
Compound 18 (major and minor)
3β,20ξ,21ξ-trihydroxy-19-oxo-21,23-epoxydammar-24-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C46H74O17	[M−H2O]+; calc. 881.4893	[M−H2O]+; measured 881.4901	ref.7
Compound 19
(3β,20S,23 S)-3,20,23trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C46H72O17	[M + Na]+; calc. 919.4662	[M + Na]+; measured 919.4612	refs21,22,35
Compound 20A
(3β,20S,23R)-3,20,23trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C46H72O17	[M + Na]+; calc. 919.4662	[M + Na]+; measured 919.4625	refs21,22
Compound 20B
(3β,20S)-3,20,21-trihydroxydammar-24-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C46H76O16	[M + Na]+; calc. 907.5026	[M + Na]+; measured 907.4995	ref.17
Compound 21 (major and minor)
23(R/S)-3β,20ξ,21(R/S)-trihydroxy-21,23-epoxydammar-24-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-β-D- glucopyranoside
White amorphous powder	C47H78O17	[M - H2O]+; calc. 897.5206	[M - H2O]+; measured 897.5219	ref.7
Compound 22 (major and minor)
23(R/S)-3β,20ξ,21(R/S)-trihydroxy-21,23-epoxydammar-24-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C46H76O16	[M - H2O]+; calc. 867.5100	[M - H2O]+; measured 867.5103	ref.7
Compound 23
(3β,20S,23S)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-glucopyranosyl-(1 → 3)]- β-D-glucopyranoside
White amorphous powder	C48H78O18	[M + H]+; calc. 943.5261	[M + H]+; measured 943.5273	ref.8
Compound 25
(3β,20S,23R)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- β-D-glucopyranoside
White amorphous powder	C47H76O17	[M + Na]+; calc. 913.5155	[M + Na]+; measured 913.5150	refs21,22
Compound 26
(3β,20S,23S)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- β-D-glucopyranoside
White amorphous powder	C47H76O17	[M + Na]+; calc. 913.5155	[M + Na]+; measured 913.5144	refs21,22
Compound 27A
(3β,20S,23R)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- α-L-arabinopyranoside
White amorphous powder	C46H74O16	[M + Na]+; calc. 905.4869	[M + Na]+; measured 905.4877	refs21,22
Compound 27B
(3β,20S,23S)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- α-L-arabinopyranoside
White amorphous powder	C46H74O16	[M + Na]+; calc. 905.4869	[M + Na]+; measured 905.4877	refs21,22
Compound 29
3β,20-dihydroxydammar-23,25-diene-21-carboxylic acid 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-β-D-glucopyranoside
White amorphous powder	C47H76O17	[M + Na]+; calc. 935.4975	[M + Na]+; measured 935.4961	ref.38
Compound 31
(3β,20S,23R)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-6-O-acetyl-β-D-glucopyranoside
White amorphous powder	C49H78O18	[M + Na]+; calc. 977.5080	[M + Na]+; measured 977.5033	ref.8
Compound 32
(3β,20S,23S)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-6-O-acetyl-β-D-glucopyranoside
White amorphous powder	C49H78O18	[M + Na]+; calc. 977.5080	[M + Na]+; measured 977.5021	ref.8
Compound 34
3β,20-dihydroxydammar-23,25-diene-21-carboxylic acid 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-β-D-6-O-acetylglucopyranoside
White amorphous powder	C49H78O18	[M + Na]+; calc. 977.5080	[M + Na]+; measured 977.5047
Compound 39
(3β,20S,23S)-3,20,23-trihydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-6-O-acetyl-β-D-glucopyranoside
White amorphous powder	C51H80O19	[M + Na]+; calc. 1019.5186	[M + Na]+; measured 1019.5140	ref.8
Compound 41
(23ξ)-21ξ-O-n-butyl-3β,20ξ,21ξ-trihydroxy-19-oxo-21,23-epoxydammar-24-ene 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-α-L-arabinopyranoside
White amorphous powder	C50H82O17	[M + Na]+; calc. 977.5444	[M + Na]+; measured 977.5407	ref.39

Figure 2.

Structure of compounds 12 and 34, and the key HMBC correlations.

Biological activity

To locate the active saponins, ten sequential time fractions (Fig. 1) from the HPLC separation were collected and screened for biological activity. GP extract fractions or compounds isolated from the fractions were incubated with pancreatic islets of either W or GK rats to determine effects on insulin release at low (3.3 mM) and high (16.7 mM) glucose concentrations. No significant insulin stimulatory activity was found in TF1-TF2, TF4-TF8 and TF10, or the flavonoid fraction (Fig. 3), while such an activity was found in TF3 and TF9. TF9 enhanced insulin release to a similar extent regardless of in the presence of 3.3 or 16.7 mM glucose. TF3 dose-dependently increased insulin release at 16.7 mM glucose, while it did not enhance insulin release at 3.3 mM glucose (Fig. 4).

Figure 3.

Result of the screening of the time fraction for biological activity by incubating the extract of the ten time fraction with pancreatic islets of either W or GK rats to determine effects on insulin release at both low (3.3 mM) and high (16.7 mM) glucose concentrations.

Figure 4.

Effects of time fraction 3 (1, 10 and 100 µg/ml) on insulin release from isolated rat islets at either 3.3 or 16.7 mM glucose. *p < 0.05; **p < 0.01 or less.

The saponins in fractions TF3 were further isolated and tested for their individual activity. Two compounds 20A and 20B in TF3 were found to stimulate insulin secretion. Compound 20B (Fig. 5) showed beneficial biological activity by only stimulating the insulin secretion at high glucose concentration (Fig. 6). This compound (20B) known as gylongiposide I has been isolated and its structure reported previously but has not been studied for its anti-diabetic activity^17–20.

Figure 5.

Structure of compound 20B (gylongiposide I).

Figure 6.

Effects of compounds 20A and 20B (1, 10 and 100 µg/ml) on insulin secretion at 3.3 and 16.7 mM glucose, from batch-incubated pancreatic islets isolated from spontaneously diabetic Goto-Kakizaki (GK) rats. *p < 0.05; **p < 0.01 or less.

Structural elucidation

Compound 12 (Fig. 2) was obtained as a white, amorphous powder, the molecular formula was established as C₄₇H₇₆O₁₈ and a molecular ion peak was observed by both positive and negative-mode ESI-MS (m/z 951.4863 [M + Na]⁺; calc. 951.4924). The ¹H-¹³C multiplicity edited HSQC NMR (CD₃OD, 600 MHz) spectrum of 12 indicated the presence of seven methyl signals at δ_H 0.86, 0.89, 0.93, 1.03, 1.03, 1.21, 1.75, twelve methylene signals, and twenty-one methine signals.

The NMR data of the aglycone moiety (Supporting Information S5e) showed characteristic resonances of carbons from one lactone carbonyl carbon δ_c 180.43, one double bond (δ_C 123.96, 142.68). COSY and TOCSY cross-peaks of H₂-1/H₂-2/H-3; H-5/H₂-6/H₂-7; H-9/H₂-11/H₂-12/H-13/H-17/H₂-16/H₂-15 and H₂-22/H-23/H-24 demonstrated the presence of vicinal coupling system. In the HMBC spectrum, two and three bond correlations of H₃-18/C-7, C-8, C-9, and C-14; H-19/C-1, C-5, C-9, and C-10; H₃-27/C-24, C-25 C-26; H₃-28, H₃-29/C-3, C-4, and C-5; H₃-30/C-8, C-13, C-14, and C-15; H₂-22/C-17, C-20, C-21, C-23, and C-24, together with the chemical shift of all protons and carbons, reveal that compound 12 had a 3,20,23,26-tetrahydroxydammar-24-en-21-oic acid-21,23-lactone aglycone structure.

The NMR data of the glycoside moiety (Supporting Information S5e) showed three anomeric signals, at δ_H/C 4.44/105.08 (H1/C1 of Glc), δ_H/C 4.46/104.79 (H1/C1 of Xyl), and δ_H/C 5.42/101.70 (H1/C1 of Rha), two hydroxymethyl groups H6/C6 of Glc (3.67, 3.85/62.47) and H5/C5 of Xyl (3.28, 3.93/67.01), one methyl group C6 of Rha (1.21/17.88) and eleven oxygen-bearing sugar carbons and their attached protons in the region δ_C 69.94–87.95, δ_H 3.26–3.98. Three spin systems were identified through TOCSY experiment. The configuration was determined to be in the α and β form based on the magnitude of the H1-H2 coupling constant β-D-Xyl (H1, d, ³J = 7.6 Hz), β-D-Glc (H1, d, ³J = 7.6 Hz), and α-L-Rha (H-1, ³J = 1.5). HMBC correlations (Fig. 2) between H-1′′ Rha (δ_H 5.42) and C-2′ Glc (δ_C 77.85), H-1′′′ Xyl (δ_H 4.46) and C-3′ Glc (δ_C 87.95), H-1′ Glc (δ_H 4.44) and C-3 on the aglycone (δ_C 89.85), demonstrated that the β-D-glucopyranosyloxy unit was located at C-3 of the aglycone and that the α-L-rhamnopyranosyloxy and β-D-xylopyranosyloxy units were linked to C-2′ and C-3′ of the glucopyranosyloxy unit respectively.

The configuration at C-20 and C-23 were determined by comparison with the most recent studies of configuration at C-20 and C-23 carried out by electronic circular dichroism (ECD) and X-ray diffraction analysis^21,22. Therefore, compound 12 was assigned to be (3β,20S,23R)-3,20,23,26-tetrahydroxydammar-24-en-21-oic acid-21,23-lactone 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]- β-D-glucopyranoside.

Compound 34 (Fig. 2) was obtained as a white, amorphous powder, the molecular formula was established as C₄₉H₇₈O₁₈ and a molecular ion peak was observed by positive-mode ESI-MS (m/z 977.5047 [M + Na]⁺; calc. 977.5080). The ¹H-¹³C multiplicity edited HSQC NMR (CD₃OD, 600 MHz) spectrum of 34 indicated the presence of eight methyl signals at δ_H 0.85, 0.87, 0.89, 0.98, 1.03, 1.21, 1.79, 2.05, four olefin signals, eleven methylene signals, and nineteen methine signals.

The NMR data of the aglycone moiety (Supporting Information S21e) showed characteristic resonances of one double bond (δ_C 126.38, 136.79), one olefin carbon (δ_C 114.97) arising from the double bond between C-25 and C-26. COSY and TOCSY cross-peaks of H₂-1/H₂-2/H-3; H-5/H₂-6/H₂-7; H-9/H₂-11/H₂-12/H-13/H-17/H₂-16/H₂-15 and H₂-22/H-23/H-24 demonstrated the presence of vicinal coupling system. In the HMBC spectrum, two and three bond correlation of H₃-18/C-7, C-8, C-9 and C-14; H-19/C-1, C-5 and C-10; H₂-26/C-27, C-24 and C-25; H₃-27/C-24, C-25 and C-26; H₃-28, H₃-29/C-3, C-4 and C-5; H₃-30/C-14 and C-15; H₂-22/C-20, C-21, C-23 and C-24; H-24/C-22, C-25 and C-26, together with the chemical shift of all protons and carbons, reveal that 34 had a 3,20-dihydroxydammar-23,25-diene-21-carboxylic acid aglycone structure.

The NMR data of the glycoside moiety (Supporting Information S21e) showed three anomeric signals, at δ_H/C 4.44/105.01 (H1/C1 of Glc), δ_H/C 4.45/104.87 (H1/C1 of Xyl), and δ_H/C 5.41/101.79 (H1/C1 of Rha), two hydroxymethyl groups H6/C6 of Glc (4.23, 4.37/64.60) and H5/C5 of Xyl (3.27, 3.93/67.01), one methyl group C6 of Rha (1.21/17.97) and eleven oxygen-bearing sugar carbons and their attached protons in the region δ_C 70.16–87.73, δ_H 3.26–3.99. Three spin systems were identified through TOCSY experiment. An acetyl group at δ_H 2.05 and δ_C 172.33, 20.76, showed HMBC correlation between H-6 of Glc and the carbonyl carbon of this acetyl group. The configuration were determined to be in the α and β form based on the coupling constant β-D-Xyl (H1, d, ³J = 7.3 Hz), β-D-Glc (H1, d, ³J = 7.6 Hz), and α-L-Rha (H-1, ³J = 1.30). HMBC correlations (Fig. 2) between H-1′′ Rha (δ_H 5.41) and C-2′ Glc (δ_C 77.92), H-1′′′ Xyl (δ_H 4.45) and C-3′ Glc (δ_C 87.73), H-1′ Glc (δ_H 4.44) and C-3 on the aglycone (δ_C 90.44), demonstrated that the β-D-6-O-acetylglucopyranosyloxy unit was located at C-3 of the aglycone and that the α-L-rhamnopyranosyloxy and β-D-xylopyranosyloxy units were linked to C-2′ and C-3′ of the glucopyranosyloxy unit respectively.

Compound 34 were assigned to be 3β,20-dihydroxydammar-23,25-diene-21-carboxylic acid 3-O-[α-L-rhamnopyranosyl-(1 → 2)]-[β-D-xylopyranosyl-(1 → 3)]-β-D-6-O-acetylglucopyranoside.

Discussion

Biological activity

We have identified and characterized the dammarane-type triterpene saponin responsible for the insulin secretion induced by a Chinese extract of the Gynostemma Pentaphyllum (GP) herbal plant. Although several of the pooled time fractions, TFs, obtained from the HPLC chromatogram, had varying degree of effect on insulin secretion from isolated islets of control W and diabetic GK rats, significant effects on the insulin-producing beta-cells were seen with one of the fractions, TF3. In addition, we found that TF3 had the most favourable antidiabetic effect by enhancing insulin release significantly only at high glucose but not at low glucose concentrations. This is in contrast to the well-known antidiabetic sulfonylurea drugs, that stimulate insulin secretion also at normoglycemia or even at lower glucose levels²³ and thereby can cause serious hypoglycemia in patients. By further chromatographic separation of the saponins present in TF3 followed by bio-assay testing we were able to determine that this favourable activity, i.e. a glucose-dependent stimulation of insulin release was entirely related to the saponin compound 20B.

In this context, it is of great importance to note that this compound most likely retains its biological activity following oral administration, since we have shown prominent antidiabetic activity in diabetic GK rats, treated orally with GP extract (0.3 g/kg body weight) for 2 weeks²⁴. In these animals, the improvement of glucose tolerance was demonstrated in parallel with augmented plasma insulin levels. A similar effect was previously reported by another compound isolated from GP extract, i.e. phanoside^12,25. However, in contrast to the present saponin 20B, phanoside did not stimulate insulin secretion in a glucose-dependent manner. Recent mechanistic studies on the GP extract demonstrated that the stimulation of insulin secretion from rat islets was mediated by effects on several steps in the stimulus-secretion coupling to glucose in the pancreatic beta cells²⁴. Among these steps are the K-ATP channels, the L-type Ca²⁺ channels, the protein kinase A activity, and pertussis-toxin sensitive exocytotic G_e-proteins.

Structure and activity

Gynostemma pentaphyllum extracts are known to possess numerous biological activities through their dammarane-type triterpene saponins. The possible structural-activity relationships (SAR) is related to the number and nature of the sugars, their acylation, the types of aglycones and the stereochemistry. A large number of studies have been conducted on anti-tumor, anti-inflammatory and anti-diabetic activities, where different structural components have been pointed out as important for the activities^2,24,26. The presence of a hydroxyl group at position C-3⁹, a double bond between C20-C22 or C20-C21²⁷, and a five membered unsaturated ketone in the side chain²⁸ in the dammarane-type structure has been mentioned as possible structural components responsible for anti-tumor activity. These results are from studies carried out on different cancer cell lines and are therefore difficult to compare. The differences in anti-inflammatory abilities have been explained by differences in sugar moieties²⁹.

From the present work, some structural features are worth noticing: The glycoside moiety at the C-3 position on the aglycone of the isolated saponins consists of a branched trisaccharide either α-L-Rha-(1 → 2)-[β-D-Xyl-(1 → 3)]-α-L-Ara, or α-L-Rha-(1 → 2)-[β-D-Xyl-(1 → 3)]-β-D-Glc. More seldom α-L-Rha-(1 → 2)-[β-D-Xyl-(1 → 3)]-β-D-Glc with acetylation on C6 of glucose and in some cases also on C4 of rhamnose. In some cases, as in compounds 8, 10, 15 and 17 an additional glucopyranose unit is attached at C-21. The aglycone moiety shows structural variability at two positions. The substituent at C-19 can be either a methyl or an aldehyde group. The greatest variability between the structures is found in the side chain attached to C-17. Ten different side chains attached to C-17 were found, some composed of five membered rings, either as lactone or hemiacetal, other as open structures with different number of double bonds and/or additional glycoside moiety attached at C-21 (Fig. 7).

Figure 7.

Structural components of the dammarane-type saponins isolated and characterized in the GP extract. The chemical structures of the 27 isolated compounds are reported in the Supporting Information S1a–S23a.

Interestingly, the potential to stimulate insulin secretion at high glucose concentration is limited to one single compound, 20B, while several saponins can stimulate insulin secretion independent of glucose concentration. Comparison of the structures of the different saponins shows that compound 10 has a structure very similar to that of 20B with the same trisaccharide unit at C-3, an aldehyde group at C-19 and the same open chain attached at C-17 with a double bond between C-24 and C-25. The only difference between the two compounds is the presence of an additional glucose residue at C-21 in compound 10. Thus, the presence of an additional sugar appears to suppress the insulin secretion at high glucose concentration.

Because of the increasing amount of data on the biological activities of saponins, rapid screening methods including activity and structural data such as LC-MS and NMR are valuable³⁰. The ¹H-¹³C HSQC NMR spectra of the 27 identified saponins together with the MS data and ¹H and ¹³C NMR chemical shifts reported in the present work should help in structural analysis when investigating new extract, and may allow for more rapid screening of already known compounds.

Experimental Procedures

Material and reagents

Gynostemma Pentaphyllum (GP) herbal extract was purchased from Hanzhong TRG Biotech Co.,Ltd. Solid phase extraction column Hypersep C-18 was purchased from Thermo scientific. Deionized water was purified by Milli-Q system from Millipore. Ethanol absolute 100% Ph.Eur, acetonitrile (HPLC grade) and methanol (HPLC grade) were purchased from VWR chemicals. Methanol D4 99.80% D (NMR) were purchased from Euriso-top. Collagenase, HEPES, bovine albumin, D-glucose, L-glutamine, RPMI 1640 culture medium, and fetal calf serum were obtained from Sigma-Aldrich, Sweden.

Extraction and isolation

The dried and powdered GP extract was dissolved in 30% ethanol solution, and applied to a Hypersep C-18 cartridge. The column was washed with 30% ethanol solution (flavonoid fraction). The saponin fraction was collected by elution with 100% ethanol. The saponin fractions were dried and further separated through preparative HPLC (Gilson 305/306 system) on a 20 × 150 mm C-18 column (Kromasil 100-5C18 HiCHROM, UK) with a binary solvent system of an aqueous (Milli-Q) 0.1% formic acid solution (A) and acetonitrile (B), with the following gradient elution: initially 30% (B) – 70% (A), changed to 50% (B) after 7 min, 50% (B) to 15 min, 60% (B) to 35 min, 80% (B) to 40 min and returned to 30% (B) after 41 min. The detection (Gilson 118 UV/VIS detector) was done at 210 nm, and a flow rate of 10 ml/min was used.

Ten sequential time fractions from the HPLC separation were collected (Fig. 1), lyophilized and stored at 4 °C until activity testing.

Furthermore, fractions 1–42 (Fig. 1) were collected and lyophilized, through repeated injection to receive sufficient material for NMR analysis to determine if the fractions contain flavonoids, saponins or other components. Some of the 42 screened compounds were not saponins and are therefore not reported. Enough material were collected through repeated injections for exhaustive structural analysis of 27 saponins fractions. The fractions were then lyophilized and purified by isocratic elution according table S24 available in the Supporting Information. Fractions 20A and 20B were co-eluting and separated by an isocratic elution (50:50) of a binary solvent system of an aqueous 0.1% formic acid solution (A) and 80:20% acetonitrile:methanol (B). The purified fractions were stored at 4 °C until NMR and LC-MS analysis.

NMR

The NMR data were recorded at 298 K with a Bruker AVANCE™ III 600 MHz spectrometer using a 5 mm ¹H/¹³C/¹⁵N/³¹P cryoprobe or a 5 mm broadband observe detection SmartProbe, both equipped with z-gradient. The ¹³C and ¹H chemical shifts were measured using CD₃OD as an internal standard (δ = 3.31 and 49.15 ppm for proton and carbon respectively). The data were acquired and processed using Bruker software. The ¹H and ¹³C resonances were assigned using homonuclear ¹H–¹H COSY, TOCSY and NOESY and heteronuclear ¹H–¹³C HSQC, HSQC–TOCSY and HMBC experiments from the Bruker pulse sequence library.

LC-MS

The LCMS analysis were carried out on isolated fractions from the crude extract with an Agilent 1100 liquid chromatography system equipped with a variable UV wavelength detector and a Kromasil^® C-18 reverse-phase (4.6 mm × 150, 5 µm) column using suitable isocratic condition for each isolated fraction of aqueous:organic solvent with the inclusion of 0.1% formic acid into both aqueous (Milli-Q) and organic phase in which the later phase consists of acetonitrile and methanol 8:2 (v/v). The flow rate was set at 1 ml/min and the UV detection wavelength was set at 210 nm to verify and screen UV peak of the compounds with their respective total ion chromatogram (TIC) peak.

The accurate mass analysis on the saponins were determined using Maxis Impact Bruker^® MS-QTOF coupled to the LC system and using Compass^® Bruker data processing software.

Animals and pancreatic islet isolation

Male diabetic GK rats and control Wistar (W) rats were used. The GK rats were bred within the department³¹, while the W rats were purchased from Charles River Ltd. The rats were maintained in a 12 h light and dark cycle and allowed food and water ad libitum. The GK rats (n = 25) had body weights ranging from 160 to 277 g, and their non-fasted plasma glucose levels were 6.4–10.9 mM, while W rats (n = 8) were 199–267 g with plasma glucose levels 4.4–5.9 mM. The animals were sacrificed by CO₂ to allow removal of pancreata for islet isolation by collagenase digestion as described³². Isolated islets were handpicked under a stereo microscope, maintained for 24 h at 37 °C and 5% CO₂ in culture dishes with RPMI 1640 medium, containing 10% heat-inactivated fetal calf serum, 2 mM L-glutamine, and 11 mM glucose prior to further experiments with incubations to determine insulin secretion^25,31,33. All methods and experimental protocols were carried out in concert with relevant guidelines and regulations. In addition, the studies were performed after approval by the laboratory animal ethics committee of the Karolinska Institutet, Stockholm.

Islet batch incubations

Isolated islets were pre-incubated for 45 min in Krebs-Ringer bicarbonate (KRB) buffer^25,33, pH 7.4, and supplemented with 10 mM HEPES, 0.2% bovine albumin and 3.3 mM glucose. Thereafter, batches of three islets were incubated in KRB buffer with 10 mM HEPES, 0.2% albumin and either 3.3 or 16.7 mM glucose. In addition, GP fractions were filtered through a 0.20 μm syringe filter prior to the incubations to remove any debris from the sample. The GP fractions were diluted to final concentrations of 100 µg/ml, 10 µg/ml, 1 µg/ml, and a control of 0 µg/ml in buffer with either glucose concentration. Each GP fraction was tested in triplicates, and each batch of islets was incubated for 60 min in 300 µl buffer in a shaking water bath at 37 °C, and then 200 µl of the incubation media was removed and stored at −18 °C until later determination of insulin. Experiments were repeated two times, and hence there were 3–6 observations from each fraction. Insulin was determined by radioimmunoassay as described³⁴.

Statistical analysis

All results from insulin secretion experiments were analysed and presented as mean and standard error of the mean (SEM): One-way Anova was performed to evaluate statistical significance of results. When this analysis indicated statistical significance, the results were further analysed by Fisher’s least significant difference. Statistical analysis was conducted on each of the individual batch incubations and therefore n = 3–6 for each of the fractions tested at each concentration. The n value varied depending on the number of replicas of the experiment conducted with triplicates. A p value < 0.05 was considered statistically significant. To allow comparisons between the groups, the mean results for each concentration of the pooled fraction, or pure saponin, were divided by their respective control at low and high glucose levels. This allowed a direct comparison between the groups since the absolute values of insulin secretion from the islets varied between rats. The results were therefore presented as fold induction of insulin release compared against 3.3 mM or 16.7 mM glucose control values.

Author Contributions

C.G.Ö., C.S. and L.L. conceived and designed the study. D.R. performed all the pancreatic islet experiments, and prepared Figure 3, 4 and 6. C.G.Ö. interpreted the data from the pancreatic islet experiments. L.L. performed the NMR experiments. E.E. and L.L. performed the LC-MS experiments. C.D. and L.L. performed the fractionation experiments of the saponins. L.L. and C.S. interpreted all NMR and LC-MS data. L.L. prepared Figure 1, 2, 5 and 7, and all figures and tables in Supplementary Information. C.G.Ö., C.S. and L.L. wrote the manuscript. All authors reviewed the final version of the manuscript.

Competing Interests

The authors declare no competing interests.

Electronic supplementary material

Supplementary information accompanies this paper at 10.1038/s41598-018-37517-3.